| Infliximab for induction and maintenance therapy for ulcerative colitis P Rutgeerts, WJ Sandborn, BG Feagan, W Reinisch, A Olson, J Johanns, ... New England Journal of Medicine 353 (23), 2462-2476, 2005 | 4865 | 2005 |
| Infliximab, azathioprine, or combination therapy for Crohn's disease JF Colombel, WJ Sandborn, W Reinisch, GJ Mantzaris, A Kornbluth, ... New England journal of medicine 362 (15), 1383-1395, 2010 | 3791 | 2010 |
| Vedolizumab as induction and maintenance therapy for ulcerative colitis BG Feagan, P Rutgeerts, BE Sands, S Hanauer, JF Colombel, ... New England Journal of Medicine 369 (8), 699-710, 2013 | 2831 | 2013 |
| Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial JF Colombel, WJ Sandborn, P Rutgeerts, R Enns, SB Hanauer, ... Gastroenterology 132 (1), 52-65, 2007 | 2824 | 2007 |
| Crohn's disease DC Baumgart, WJ Sandborn The Lancet 380 (9853), 1590-1605, 2012 | 2761 | 2012 |
| Inflammatory bowel disease: clinical aspects and established and evolving therapies DC Baumgart, WJ Sandborn The Lancet 369 (9573), 1641-1657, 2007 | 2565 | 2007 |
| Vedolizumab as induction and maintenance therapy for Crohn's disease WJ Sandborn, BG Feagan, P Rutgeerts, S Hanauer, JF Colombel, ... New England Journal of Medicine 369 (8), 711-721, 2013 | 2485 | 2013 |
| Human anti–tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I Trial SB Hanauer, WJ Sandborn, P Rutgeerts, RN Fedorak, M Lukas, ... Gastroenterology 130 (2), 323-333, 2006 | 2180 | 2006 |
| Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target L Peyrin-Biroulet, W Sandborn, BE Sands, W Reinisch, W Bemelman, ... Official journal of the American College of Gastroenterology| ACG 110 (9 …, 2015 | 1972 | 2015 |
| Ustekinumab as induction and maintenance therapy for Crohn’s disease BG Feagan, WJ Sandborn, C Gasink, D Jacobstein, Y Lang, JR Friedman, ... New England journal of medicine 375 (20), 1946-1960, 2016 | 1952 | 2016 |
| Tofacitinib as induction and maintenance therapy for ulcerative colitis WJ Sandborn, C Su, BE Sands, GR D’Haens, S Vermeire, S Schreiber, ... New England Journal of Medicine 376 (18), 1723-1736, 2017 | 1883 | 2017 |
| STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD … D Turner, A Ricciuto, A Lewis, F D’amico, J Dhaliwal, AM Griffiths, ... Gastroenterology 160 (5), 1570-1583, 2021 | 1839 | 2021 |
| The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study WA Faubion Jr, EV Loftus Jr, WS Harmsen, AR Zinsmeister, WJ Sandborn Gastroenterology 121 (2), 255-260, 2001 | 1564 | 2001 |
| A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 C Gasche, J Scholmerich, J Brynskov, G D'Haens, SB Hanauer, EJ Irvine, ... Inflammatory bowel diseases 6 (1), 8-15, 2000 | 1554 | 2000 |
| Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial G D'Haens, F Baert, G van Assche, P Caenepeel, P Vergauwe, ... The Lancet 371 (9613), 660-667, 2008 | 1486 | 2008 |
| Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis WJ Sandborn, G Van Assche, W Reinisch, JF Colombel, G D’Haens, ... Gastroenterology 142 (2), 257-265. e3, 2012 | 1441 | 2012 |
| Certolizumab pegol for the treatment of Crohn's disease WJ Sandborn, BG Feagan, S Stoinov, PJ Honiball, P Rutgeerts, D Mason, ... New England journal of medicine 357 (3), 228-238, 2007 | 1428 | 2007 |
| Stapling apparatus and methods of assembling or operating the same WJ Sandborn, E Rajan US Patent App. 13/301,294, 2012 | 1426 | 2012 |
| The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota DA Schwartz, EV Loftus Jr, WJ Tremaine, R Panaccione, WS Harmsen, ... Gastroenterology 122 (4), 875-880, 2002 | 1360 | 2002 |
| Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis WJ Sandborn, BG Feagan, C Marano, H Zhang, R Strauss, J Johanns, ... Gastroenterology 146 (1), 85-95, 2014 | 1352* | 2014 |